CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER

First cancer vaccine that was approved for routine therapy was sipuleucel-T for treatment of patients with metastatic castration resistant prostate cancer. However, other immunotherapy drugs evaluated in prostate cancer, particularly immune checkpoint inhibitors, have failed to show therapeutic effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Šamija, Ivan, Fröbe, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2019
Materias:
Professional Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693557/
https://www.ncbi.nlm.nih.gov/pubmed/34975203
http://dx.doi.org/10.20471/acc.2019.58.s2.13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693557/
https://www.ncbi.nlm.nih.gov/pubmed/34975203
http://dx.doi.org/10.20471/acc.2019.58.s2.13

Ejemplares similares